Where to meet us

We are attending conferences to meet with new investment opportunities.

Novo Nordisk Biotech Fund

Novo Nordisk Biotech Fund is the corporate venture fund of  Novo Nordisk A/S responsible for the company's venture capital activities.

We provide venture capital to biotech companies possessing pioneering technologies and competencies of strategic interest to Novo Nordisk A/S. 

Latest news

• Feb 7, 2012
  Pieris announces the receipt of a EUR 1M grant to support the development of the company's proprietary PRS-110 compound targeting c-Met, a cellular receptor that
  plays a key role in cancer cell growth and metastasis
  
  
• Nov 15, 2011
  Pieris announces results and successful completion of its PRS-050 Anticalin Phase I trial at AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference
   
• Oct 19, 2011
  Pieris outlines strategic impact of six million euro EUROCALIN Grant Award on anticalin pipeline development